Medicare CED Decisions By Local Contractors Would Be Unworkable, Drug Firms Argue
In comments to the Centers for Medicare and Medicaid Services, drug manufacturers also say CED should continue to be applied only “rarely” for drugs and biologics and should not apply to off-label uses.
You may also be interested in...
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.